Fujifilm Corporation on Thursday announced that it is investing $1.2 billon to bolster its end-to-end manufacturing capacity at the company’s Holly Springs, North Carolina site.
Novartis announced Thursday an exclusive strategic partnership with Arvinas to advance an oral protein degrader for prostate cancer, while also announcing the tender offer for its $2.9 billion acquisition of MorphoSys has commenced.
Vertex Pharmaceuticals on Wednesday scooped up clinical-stage immunotherapy company Alpine Immune Sciences for $4.9 billion in cash in the largest acquisition of 2024, targeting autoimmune and inflammatory diseases.
German packaging and medical equipment maker Gerresheimer has contracts with the leading players in the burgeoning weight-loss drugs sector, CEO Dietmar Siemssen said after the company reported first-quarter earnings on Thursday.
Drugmaker AstraZeneca plans to raise its annual dividend by 7% for 2024, it said on Thursday, ahead of a shareholder vote on a hefty boost to its chief executive’s pay package.
Los Angeles-based startup TORL BioTherapeutics on Wednesday closed a $158 million oversubscribed Series B-2 funding round, which will go toward the advancement of its pipeline of novel antibody-drug conjugates for oncology.
The American Association for Cancer Research’s annual conference kicks off Friday as more than 20,000 attendees descend on San Diego. Analysts and researchers who spoke with BioSpace said they’re looking forward to early scientific data, and antibody-drug conjugates (ADCs) will be a key focus.
Philips announced the main terms of an agreement it reached in January with the U.S. government on its new sleep apnea machines, which has already cost the company over 360 million euros in the fourth quarter of 2023, sending its shares up almost 3% on Wednesday.
Moderna shares rose 8% in morning trade on Tuesday after the company’s individualized cancer vaccine developed with Merck showed positive response in an early-stage trial in patients with a type of head and neck cancer.
Two biotechs, Nvelop Therapeutics and Seaport Therapeutics, emerged from stealth Tuesday with $100 million in financing as they look to target the neuropsychiatric and gene editing spaces, respectively.
